Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Infectious Disease

Understanding the Biology of Dengue Fever

At a Glance

Dengue fever is a mosquito-borne virus that attacks the circulatory system, sometimes causing dangerous blood vessel leakage. A second infection is often much more severe because old antibodies act like a Trojan horse, helping the new virus multiply faster and trigger severe inflammation.

Dengue fever is a viral illness that affects millions of people worldwide. While often called “breakbone fever” due to the intense joint and muscle pain it causes, the most significant biological impacts of the virus happen deep within your circulatory and immune systems. Understanding how the virus enters your body and how your immune system responds is key to managing the illness.

How Dengue Spreads

The Dengue virus (DENV) does not spread directly from person to person. Instead, it relies on a specific cycle between humans and mosquitoes [1].

  • The Mosquito Vector: The virus is primarily carried by Aedes aegypti and Aedes albopictus mosquitoes [2]. When a mosquito bites a person who has the virus in their blood, the mosquito becomes infected [3].
  • The Incubation Period: The virus must live inside the mosquito for several days—a period influenced by environmental temperature—before it can be passed to the next person [4].
  • Human Infection: Once an infected mosquito bites a human, the virus begins to replicate (multiply) in the body, leading to the symptoms of the disease [3].

The Biology of “Leaky” Blood Vessels

The most dangerous aspect of severe Dengue is not the virus itself, but how it affects your blood vessels. This is often referred to as vascular leakage or plasma leakage [5].

Your blood vessels are lined with a protective “non-stick” coating called the glycocalyx, which helps keep fluids inside the vessels [6]. The Dengue virus produces a specific protein called NS1. This protein acts like a toxin that directly attacks and degrades this protective coating [7]. When the coating is damaged, the walls of the blood vessels become permeable or “leaky” [8].

As a result, plasma (the liquid part of your blood) leaks out of the vessels and into the surrounding body cavities [5]. This can lead to a dangerous drop in blood pressure and a concentration of red blood cells, a condition doctors monitor closely by checking your hematocrit levels [5][9].

The Immune System’s “Cytokine Storm”

While the virus is attacking the blood vessels, your immune system is working overtime to fight back. However, in some cases, the immune response becomes overactive, leading to what is known as a cytokine storm [10].

Cytokines are chemical messengers that tell your immune cells what to do. In severe Dengue, the body releases an overwhelming flood of these chemicals, including TNF-alpha and IL-6 [10][11]. Instead of just fighting the virus, this “storm” of chemicals further damages the lining of the blood vessels, making the leakage even worse [12][13].

Why the Second Infection is Often Worse

There are four different types (serotypes) of the Dengue virus. If you are infected with one, you gain lifelong immunity to that specific type, but only short-term protection against the others [14].

A phenomenon called Antibody-Dependent Enhancement (ADE) explains why a second infection with a different type of Dengue can be much more severe than the first [15].

  1. Old Antibodies: During a second infection, your body uses the antibodies it made during the first infection to try to fight the new virus [14].
  2. The “Trojan Horse” Effect: Because these old antibodies aren’t a perfect match for the new virus type, they cannot neutralize it. Instead, they stick to the new virus and actually help it enter your immune cells more easily [16].
  3. Increased Viral Load: Once inside these cells, the virus multiplies much faster than it would have otherwise [17].
  4. Escalated Response: This higher amount of virus triggers a much more violent immune response, increasing the risk of a cytokine storm and severe plasma leakage [18][19].

This biological interaction is why healthcare providers are particularly vigilant when treating a patient who has previously been diagnosed with Dengue [15].

Common questions in this guide

Why is a second Dengue fever infection often worse than the first?
A second infection with a different Dengue virus type can trigger Antibody-Dependent Enhancement (ADE). Your old antibodies bind to the new virus but fail to neutralize it, acting like a Trojan horse that helps the virus enter immune cells and multiply faster.
What is vascular leakage in severe Dengue fever?
Vascular leakage occurs when the Dengue virus produces a protein called NS1 that damages the protective coating inside your blood vessels. This causes plasma to leak out into surrounding body cavities, leading to a dangerous drop in blood pressure.
What are the warning signs of severe Dengue fever?
Warning signs of severe Dengue infection include severe abdominal pain, persistent vomiting, and bleeding from the gums. If you experience any of these symptoms, especially after a fever starts to drop, seek immediate medical attention.
How does the Dengue virus cause a cytokine storm?
When fighting the virus, your immune system may overreact and release an overwhelming flood of chemical messengers called cytokines. Instead of just clearing the virus, this severe inflammatory response further damages blood vessels and worsens plasma leakage.
Can I catch Dengue directly from another person?
No, Dengue virus does not spread directly from person to person. It is transmitted exclusively through the bites of infected Aedes mosquitoes that have previously bitten someone carrying the virus.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How do we monitor if my body is entering the 'critical phase' of plasma leakage?
  2. 2.Based on my symptoms and tests, do you see signs of a 'cytokine storm' starting?
  3. 3.If I have had Dengue before, how does that change the monitoring or treatment plan for this infection?
  4. 4.What specific signs of 'vascular leakage' should I be watching for at home?
  5. 5.Can we test for my NS1 protein levels to help predict the risk of severe disease?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Is Dengue Fever Contagious From Person to Person?Why Is a Second Dengue Infection Worse? | Inciteful Med

References

References (19)
  1. 1

    Vertical transmission of Dengue virus type-3 and metagenomic virome profiles of Aedes aegypti mosquitoes collected in Kisumu, Kenya.

    Wanjiru T, Bulimo W, Langat S, et al.

    PloS one 2025; (20(7)):e0315492 doi:10.1371/journal.pone.0315492.

    PMID: 40601719
  2. 2

    The Mosquito Immune System and the Life of Dengue Virus: What We Know and Do Not Know.

    Mukherjee D, Das S, Begum F, et al.

    Pathogens (Basel, Switzerland) 2019; (8(2)) doi:10.3390/pathogens8020077.

    PMID: 31200426
  3. 3

    Mammalian-targeted antiviral peptide reduces dengue virus type 1 infection in Aedes aegypti.

    Medina-Carrasco D, Santiago GC, Garay Pérez HE, et al.

    Antiviral research 2025; (241()):106241 doi:10.1016/j.antiviral.2025.106241.

    PMID: 40701277
  4. 4

    The effect of temperature on dengue virus transmission by Aedes mosquitoes.

    Liu Z, Zhang Q, Li L, et al.

    Frontiers in cellular and infection microbiology 2023; (13()):1242173 doi:10.3389/fcimb.2023.1242173.

    PMID: 37808907
  5. 5

    Association of dengue virus non-structural-1 protein with disease severity: a brief review.

    Ghetia C, Bhatt P, Mukhopadhyay C

    Transactions of the Royal Society of Tropical Medicine and Hygiene 2022; (116(11)):986-995 doi:10.1093/trstmh/trac087.

    PMID: 36125197
  6. 6

    Dengue virus NS1 cytokine-independent vascular leak is dependent on endothelial glycocalyx components.

    Glasner DR, Ratnasiri K, Puerta-Guardo H, et al.

    PLoS pathogens 2017; (13(11)):e1006673 doi:10.1371/journal.ppat.1006673.

    PMID: 29121099
  7. 7

    Dengue Virus NS1 Disrupts the Endothelial Glycocalyx, Leading to Hyperpermeability.

    Puerta-Guardo H, Glasner DR, Harris E

    PLoS pathogens 2016; (12(7)):e1005738 doi:10.1371/journal.ppat.1005738.

    PMID: 27416066
  8. 8

    Dengue virus NS1 hits hard at the barrier integrity of human cerebral microvascular endothelial cells via cellular microRNA dysregulations.

    Apoorva , Kumar A, Singh SK

    Tissue barriers 2025; (13(3)):2424628 doi:10.1080/21688370.2024.2424628.

    PMID: 39508307
  9. 9

    Dengue virus modulates the fibrinolytic system to drive vascular leakage and serves as a therapeutic target for tranexamic acid.

    Wang WH, Lin CY, Huang S, et al.

    European journal of pharmacology 2026; (1015()):178553 doi:10.1016/j.ejphar.2026.178553.

    PMID: 41539348
  10. 10

    Dengue hemorrhagic fever and the liver.

    Leowattana W, Leowattana T

    World journal of hepatology 2021; (13(12)):1968-1976 doi:10.4254/wjh.v13.i12.1968.

    PMID: 35070001
  11. 11

    Fulminant Hepatic Failure in Dengue Fever Without Plasma Leakage: A Case Report.

    Arunpriyandan V, Sundaresan KT

    Cureus 2022; (14(4)):e23964 doi:10.7759/cureus.23964.

    PMID: 35547461
  12. 12

    Altered Moesin and Actin Cytoskeleton Protein Rearrangements Affect Transendothelial Permeability in Human Endothelial Cells upon Dengue Virus Infection and TNF-α Treatment.

    Suttitheptumrong A, Mahutchariyakul T, Rawarak N, et al.

    Viruses 2021; (13(10)) doi:10.3390/v13102042.

    PMID: 34696472
  13. 13

    Grape Seed Proanthocyanidins Inhibit Replication of the Dengue Virus by Targeting NF-kB and MAPK-Mediated Cyclooxygenase-2 Expression.

    Chen WC, Hossen M, Liu W, et al.

    Viruses 2023; (15(4)) doi:10.3390/v15040884.

    PMID: 37112864
  14. 14

    Understanding antibody-dependent enhancement in dengue: Are afucosylated IgG1s a concern?

    Teo A, Tan HD, Loy T, et al.

    PLoS pathogens 2023; (19(3)):e1011223 doi:10.1371/journal.ppat.1011223.

    PMID: 36996026
  15. 15

    A simple mathematical model to describe antibody-dependent enhancement in heterologous secondary infection in dengue.

    Cerón Gómez M, Yang HM

    Mathematical medicine and biology : a journal of the IMA 2019; (36(4)):411-438 doi:10.1093/imammb/dqy016.

    PMID: 30299478
  16. 16

    The role of IgG Fc receptors in antibody-dependent enhancement.

    Bournazos S, Gupta A, Ravetch JV

    Nature reviews. Immunology 2020; (20(10)):633-643 doi:10.1038/s41577-020-00410-0.

    PMID: 32782358
  17. 17

    Antibody-Dependent Dengue Virus Entry Modulates Cell Intrinsic Responses for Enhanced Infection.

    Chan CYY, Low JZH, Gan ES, et al.

    mSphere 2019; (4(5)) doi:10.1128/mSphere.00528-19.

    PMID: 31533998
  18. 18

    Dengue hemorrhagic fever - A systemic literature review of current perspectives on pathogenesis, prevention and control.

    Wang WH, Urbina AN, Chang MR, et al.

    Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2020; (53(6)):963-978 doi:10.1016/j.jmii.2020.03.007.

    PMID: 32265181
  19. 19

    Host factors and genetic polymorphisms influencing dengue infection.

    Mehak MA, Khan M, Razu MH

    Virus research 2025; (360()):199623 doi:10.1016/j.virusres.2025.199623.

    PMID: 40846152

This page provides educational information about the biology of Dengue fever. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a healthcare provider if you suspect a Dengue infection.

Get notified when new evidence is published on Dengue fever.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.